Surrogate end points of quality of life assessment: Have we really found what we are looking for?

Health and Quality of Life Outcomes

Volumn 1, Issue , 2003, Pages

  Tassinari, Davide ^a  

^a City Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUOROURACIL; GEMCITABINE; GESTAGEN; MEDROXYPROGESTERONE; MEGESTROL ACETATE; MITOXANTRONE; OPIATE; PREDNISONE;

ANALGESIA; ARTICLE; CACHEXIA; CANCER; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HORMONE RESISTANCE; HUMAN; MEDICAL DECISION MAKING; ONCOLOGY; OUTCOMES RESEARCH; PANCREAS CANCER; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; VALIDATION PROCESS; MEDICAL RESEARCH; METHODOLOGY; NEOPLASM; OUTCOME ASSESSMENT; PALLIATIVE THERAPY;

BIOMEDICAL RESEARCH; HUMANS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PALLIATIVE CARE; QUALITY OF LIFE;

EID: 4243142733     PISSN: 14777525     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-7525-1-71     Document Type: Article

References (40)

1. Apolone G: Clinical and outcome research in oncology. The need for integration. Health and Quality of Life Outcomes 2003, 1:3.
2. Lee SJ, Earle CC, Weeks JC: Outcomes research in oncology: history, conceptual framework and trends in the literature. J Natl Cancer Inst 2000, 92:195-204.
3. ASCO Special Article: Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996, 14:671-9.
4. Schilsky RL: End points in cancer clinical trials and the drugs approval process. Clin Cancer Res 2002, 8:935-8.
5. Johnson JR, Williams G, Pazdur R: End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003, 21:1404-11.
6. Apolone G, De Carli G, Brunetti M, Garattini S: Health-related quality of life (HR-QOL) and regulatory issues. An assessment of the European Agency for the Evaluation of Medical Products (EMEA) recommendation on the use of HR-QOL measures in drug approval. Pharmacoeconomics 2001, 19:187-95.
7. Sanders C, Egger M, Donovan J, Tallon D, Frankel S: Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ 1998, 317:1191-4.
8. Panzini I, Tassinari D, Monticelli G, Sermasi A, Roudnas B, Arcangeli V, Papi M, Fochessati F, Poggi B, Ravaioli A: Quality of life (QoL) in randomized clinical trials (RCT): a critical review of literature. [abstract]. Proc Am Soc Clin Oncol J Clin Oncol 2003, 22:a2952.
9. Levine MN, Ganz PA: Beyond the development of quality-of-life instruments: where do we go from here? J Clin Oncol 2002, 20:2215-6.
10. Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R: Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ 2002, 324:1417-21.
11. Carr AJ, Higginson IJ: Are quality of life measures patient centred? BMJ 2001, 322:1357-60.
12. Bland MJ, Altman DG: Validating scales and indexes. BMJ 2002, 324:606-7.
13. Bottomley A: The cancer patient and quality of life. The Oncologist 2002, 7:120-5.
14. Carr AJ, Gibson B, Robinson PG: Is quality of life determined by expectations or experience? BMJ 2001, 322:1240-3.
15. Higginson IJ, Carr AJ: Using quality of life measures in the clinical setting. BMJ 2001, 322:1297-300.
16. Muldoon MF, Barger SD, Flory JD, Manuck SB: What are quality of life measurements measuring? BMJ 1998, 316:542-5.
17. Cella D, Chang CH, Lai JS, Webster K: Advances in quality of life measurements in oncology patients. Semin Oncol 2002, 29(3 suppl 8):60-8.
18. Rothemberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA III, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996, 7:347-53.
19. Burris HA III, Moore MJ, Andersen J, Green MR, Rothemberg ML, Modiano MR, Cripps MC, Portenoy RK, Starniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Van Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-13.
20. Verweij J: The benefit of clinical benefit: a European perspective. Ann Oncol 1996, 7:333-334.
21. Gelber RD: Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective. Ann Oncol 1996, 7:335-7.
22. Caraceni A, De Conno F: Analgesic effect of chemotherapy? J Clin Oncol 1998, 16:803.
23. Ballatori E, Del Favero A, Roila F: Clinical benefit as a primary efficacy endpoint. J Clin Oncol 1998, 16:803-4.
24. Steer CB, Marx GM, Harper PG: Is there quality in clinical benefit? Ann Oncol 2001, 12:1191-3.
25. Hoffman K, Glimelius B: Evaluation of clinical benefit of chemotherapy in patients with upper gastrointestinal cancer. Acta Oncol 1998, 37:651-9.
26. Vansteenkiste JF, Vandebroek JE, Nackaerts KL, Weynants P, Valcke YJ, Verresen DA, Devogelaere RC, Marien SA, Humblet YP, Dams NL, The Leuven Lung Cancer Group: Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 2001, 12:1221-30.
27. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CML, Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a canadian randomized trial with palliative end points. J Clin Oncol 1996, 14:1756-64.
28. Vogelzang NJ: One hundred thirteen men with hormonerefractory prostate cancer died today. J Clin Oncol 1996, 14:1753-5.
29. Denes AE: Chemotherapy with mitoxantrone in hormonerefractory prostate cancer. J Clin Oncol 1997, 15:410-1.
30. Browman GP: Science, language, intuition, and many meanings of quality of life. J Clin Oncol 1999, 17:1651-3.
31. Osoba D, Tannock IF, Ernst DS, Neville A: Heath-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999, 17:1654-63.
32. Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P, Willan AR, Ernst S, Moore MJ, Neville A, Tannock IF: Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a canadian randomized trial with palliative end points. J Clin Oncol 1998, 16:2272-9.
33. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudo S, Averbuch S, Macleod A, Fayereislova A, Baselga J: Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). [abstract]. J Clin Oncol 2002, 21:298a.
34. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis C, Albain KS, Brahmer JR, Sandler A, Crawford J, Lutzker SG, Lilenbaum R, Helms L, Wolf M, Averbuch S, Ochs J, Kay A: A phase II trial of ZD1839 ('Iressa') in advanced nonsmall cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). [abstract]. J Clin Oncol 2002, 21:292a.
35. Herbst RS: Dose-comparative monotherapy trials of ZD1839 in previously treated Non-Small Cell Lung Cancer patients. Semin Oncol 2003, 30(1 supplement 1):30-38.
36. Cella D: Impact of ZD1839 on Non-Small Cell Lung Cancer-related symptoms as measured by the Functional Assessment of Cancer Therapy-Lung Scale. Semin Oncol 2003, 30(1 supplement 1):39-48.
37. Kaasa S, Loge JH: Quality of life in palliative care: principles and practice. Palliat Med 2003, 17:11-20.
38. Kaasa S, Loge JH: Quality of life assessment in palliative care. The Lancet Oncology 2002, 3:175-82.
39. ASCO Special Article: Cancer care during the last phase of life. J Clin Oncol 1998, 16:1986-96.
40. Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D: High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol 2001, 12:289-300.